BACKGROUND: A comprehensive evaluation of dysarthria is required to make an accurate differential diagnosis with other communication disorders and plan effective rehabilitation programs. The Frenchay Dysarthria Assessment-2 (FDA-2) is a valid, reliable and widely-used protocol for the assessment of dysarthria. An Italian version of the FDA-2 is currently lacking. AIM: To perform a cross-cultural adaptation of the FDA-2 in Italian and to validate the Italian version of the FDA-2. DESIGN: Validation study. SETTING: Inpatient rehabilitation center. POPULATION: 69 patients with dysarthria and 112 healthy controls. METHODS: The FDA-2 was translated and cross-culturally adapted to Italian. The validation study was carried out in 4 steps: (1) 42 audio-recorded samples of FDA-2 items from 11 patients with dysarthria were independently assessed by 7 speech and language pathologists for interrater reliability and re-assessed after 6 weeks for intrarater reliability; (2) 11 patients were simultaneously assessed by 3 speech and language therapists for interrater reliability of the whole Italian version of the FDA-2 and re-assessed within 24 hours for test-retest reliability; (3) the Italian version of the FDA-2 was administered to 112 healthy volunteers to gain normative data; (4) 49 patients with different types of dysarthria were assessed using the Italian version of the FDA-2, the Therapy Outcome Measure impairment scale and the Robertson Profile for the validity analysis. RESULTS: Interrater and intrarater reliability ranged from good to excellent (ICC >0.75) except for 3 audiorecorded items. The overall protocol demonstrated excellent (ICC >0.9) inter-rater and test-retest reliability for all the sections and the total score. Normative data were gained for 6 age groups. For the validity analysis, a statistically significant difference was found between dysarthric patients and healthy subjects for all sections and the total score. The FDA-2 significantly correlated to the Therapy Outcome Measure (r=0.75) and the Robertson Profile (r=0.81). CONCLUSIONS: The Italian version of the FDA-2 yield satisfactory reliability and validity, comparable to the psychometric properties of the original version. CLINICAL REHABILITATION IMPACT: Speech and language pathologists can rely on a valid and reliable tool in Italian for the assessment of dysarthria in both clinical and research practice.

Cross-cultural adaptation into italian and validation of the Frenchay Dysarthria Assessment-2 / V. Riolo, N. Pizzorni, E. Guanziroli, B. Agostinis, M. Confortola, N. Schettino, G. Gilardone, A. Schindler, F. Molteni. - In: EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE. - ISSN 1973-9095. - (2021). [Epub ahead of print] [10.23736/S1973-9087.21.07029-5]

Cross-cultural adaptation into italian and validation of the Frenchay Dysarthria Assessment-2

N. Pizzorni
Secondo
;
A. Schindler
Penultimo
;
2021

Abstract

BACKGROUND: A comprehensive evaluation of dysarthria is required to make an accurate differential diagnosis with other communication disorders and plan effective rehabilitation programs. The Frenchay Dysarthria Assessment-2 (FDA-2) is a valid, reliable and widely-used protocol for the assessment of dysarthria. An Italian version of the FDA-2 is currently lacking. AIM: To perform a cross-cultural adaptation of the FDA-2 in Italian and to validate the Italian version of the FDA-2. DESIGN: Validation study. SETTING: Inpatient rehabilitation center. POPULATION: 69 patients with dysarthria and 112 healthy controls. METHODS: The FDA-2 was translated and cross-culturally adapted to Italian. The validation study was carried out in 4 steps: (1) 42 audio-recorded samples of FDA-2 items from 11 patients with dysarthria were independently assessed by 7 speech and language pathologists for interrater reliability and re-assessed after 6 weeks for intrarater reliability; (2) 11 patients were simultaneously assessed by 3 speech and language therapists for interrater reliability of the whole Italian version of the FDA-2 and re-assessed within 24 hours for test-retest reliability; (3) the Italian version of the FDA-2 was administered to 112 healthy volunteers to gain normative data; (4) 49 patients with different types of dysarthria were assessed using the Italian version of the FDA-2, the Therapy Outcome Measure impairment scale and the Robertson Profile for the validity analysis. RESULTS: Interrater and intrarater reliability ranged from good to excellent (ICC >0.75) except for 3 audiorecorded items. The overall protocol demonstrated excellent (ICC >0.9) inter-rater and test-retest reliability for all the sections and the total score. Normative data were gained for 6 age groups. For the validity analysis, a statistically significant difference was found between dysarthric patients and healthy subjects for all sections and the total score. The FDA-2 significantly correlated to the Therapy Outcome Measure (r=0.75) and the Robertson Profile (r=0.81). CONCLUSIONS: The Italian version of the FDA-2 yield satisfactory reliability and validity, comparable to the psychometric properties of the original version. CLINICAL REHABILITATION IMPACT: Speech and language pathologists can rely on a valid and reliable tool in Italian for the assessment of dysarthria in both clinical and research practice.
Dysarthria; Speech-language pathology; Validation study;
Settore MED/50 - Scienze Tecniche Mediche Applicate
Settore MED/32 - Audiologia
Settore MED/31 - Otorinolaringoiatria
9-set-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
R33Y9999N00A21090905.pdf

embargo fino al 09/09/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.25 MB
Formato Adobe PDF
2.25 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/870714
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact